Article Text

Download PDFPDF
Primary Treatment and Prognostic Factors of Carcinosarcoma of the Ovary, Fallopian Tube, and Peritoneum: A Taiwanese Gynecologic Oncology Group Study
  1. Chien-Hsing Lu, MD, PhD*,,
  2. I-Hui Chen, MD,
  3. Yi-Jen Chen, MD, PhD,§,
  4. Kung-Liahng Wang, MD,,#,
  5. Jian-Tai Timothy Qiu, MD, PhD**,††,
  6. Hao Lin, PhD††,‡‡,
  7. Wu-Chou Lin, MD§§,
  8. Wen-Shiung Liou, MD∥∥,
  9. Yu-Fang Huang, MD¶¶,
  10. Yue-Shan Lin, MD##,
  11. Yi-Torng Tee, MD*** and
  12. Yao-Ching Hung, MD, PhD§§,†††
  1. *Department of Obstetrics and Gynecology, Taichung Veterans General Hospital, Taichung;
  2. Department of Obstetrics and Gynecology, National Yang-Ming University, Taipei;
  3. Obstetrics and Gynecology Department, National Taiwan University Hospital, Hsin-Chu branch, Hsin-Chu;
  4. §Department of Obstetrics and Gynecology, Taipei Veterans General Hospital;
  5. Department of Obstetrics and Gynecology, Mackay Memorial Hospital;
  6. Department of Nursing, Mackay Medicine, Nursing and Management College;
  7. #Department of Obstetrics and Gynecology, Taipei Medical University, Taipei;
  8. **Department of Obstetrics and Gynecology, Chang Gung Memorial Hospital;
  9. ††Chang Gung University College of Medicine, Taoyuan;
  10. ‡‡Department of Obstetrics and Gynecology, Chang Gung Memorial Hospital-Kaohsiung, Kaohsiung;
  11. §§Department of Obstetrics and Gynecology, China Medical University Hospital, Taichung;
  12. ∥∥Department of Obstetrics and Gynecology, Kaohsiung Veterans General Hospital, Kaohsiung;
  13. ¶¶Department of Obstetrics and Gynecology, National Cheng Kung University and Hospital;
  14. ##Department of Obstetrics and Gynecology, Chi-Mei Medical Center, Tainan;
  15. ***Department of Obstetrics and Gynecology, Chung Shan Medical University Hospital, Taichung; and
  16. †††College of Medicine, China Medical University, Taichung, Taiwan.
  1. Address correspondence and reprint requests to Yao-Ching Hung, MD, PhD, Department of Obstetrics and Gynecology, China Medical University Hospital, No. 2, Yuh-Der Rd, Taichung 404, Taiwan. E-mail: d6375{at}mail.cmuh.org.tw.

Abstract

Objective This study aimed to determine the clinical prognostic factors involved in carcinosarcoma of the ovary, fallopian tube, and peritoneum.

Materials and Methods This retrospective study was undertaken by the Taiwanese Gynecologic Oncology Group. The retrieved clinical data included demographic characteristics, medical disease, tumor status, extent of surgery, and adjuvant chemotherapy.

Results In total, 63 patients with carcinosarcoma of the ovary, fallopian tube, and peritoneum were identified. Sixty-one patients with complete data were enrolled for further data analysis. The mean follow-up period was 1.0 year, and the mean overall survival was 15.4 months. By log-rank tests, age, menopausal status, parity, hypertension, diabetes, primary tumor size, para-aortic lymph node metastasis, pretreatment CA-125, preceding diagnostic surgery, hysterectomy, lymphadenectomy, other surgeries, and paclitaxel use were not predictive of overall survival.

Omentectomy, no gross residual implants after surgery, platinum treatment, and no pelvic lymph node metastasis had a trend toward better survival. Early diagnosis at stage I and cisplatin/ifosfamide regimen were significant associated with a better overall survival in log-rank and simple Cox regression tests. Bilateral ovarian tumors and metastatic tumors larger than 2 cm were significantly associated with a poorer overall survival.

Conclusions Early diagnosis at stage I, unilateral ovarian tumor, metastatic tumors less than 2 cm, and cisplatin/ifosfamide regimen were predictive of a better survival.

Omentectomy and complete debulking surgery also showed a trend toward better survival. Thus, these treatment strategies should be applied in patients with carcinosarcoma of the ovary, fallopian tube, and peritoneum.

  • Carcinosarcoma
  • Malignant mixed Müllerian tumor
  • Ovarian cancer
  • Ifosfamide
  • Paclitaxel
  • Debulking operation

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Footnotes

  • Details of ethics approval: Institutional review board, Taichung Veterans General Hospital, No. C10242. Date of approval: Jan. 12, 2011, and institutional review board from each participating hospital.

  • The authors declare no conflicts of interest.